Abstract:Hypoxia-ischemia is the most common cause of neonatal encephalopathy (NE). In most cases, an intrapartum event is presumed to lead to perinatal hypoxia ischemia, but the exact pathogenesis, and therefore timing, are often not known. 1 In well-resourced settings, therapeutic hypothermia (TH) reduces death and major neurodevelopmental disability in infants with NE. 2 However, there is heterogeneity in outcomes, and major neurodevelopmental disability is still seen in about one third of survivors who are treated with therapeutic hypothermia. 3 The heterogeneity in response of NE to TH means alternative treatments are desperately sought. As such, many biomarkers have been studied as surrogate measures of long-term outcome, in order to expedite assessment of potential treatments. Moreover, an important goal is to personalize treatment for NE such that individuals who might benefit from a different approach to TH, might be detected early. It is also important to study biomarkers that can discriminate between which babies benefit from TH versus those who may be at higher risk of an adverse outcome. 4 In the study by O'Gorman Tuura et al., the authors have explored the link between perfusion and neurodevelopmental outcomes using arterial spine labeling (ASL) as a neuroimaging marker for outcome prediction. 5 ASL is a noninvasive magnetic resonance imaging (MRI) technique in which protons in blood and water are magnetically labeled and the signal generated by the endogenous labels are detected by subtracting MRI signals during alternating labeled and unlabeled acquisitions. The images demonstrate signal intensity proportional to the amount of perfusion in each voxel and a quantitative measurement of cerebral blood flow (CBF) can be calculated. 6 Previous authors have described patterns of CBF using ASL in NE. Wintermark et al. demonstrated initial hypoperfusion on day 1 followed by hyperperfusion at days 2–3. 7 A study by Tang et al. reported lower CBF values in neonates with NE at 0–24 h and 3–7 days with higher values in the 1–3 day-old group. 8 The mean age at MRI in O'Gorman Tuura's paper was 5 days (range 3–9 days), which means that any hyperperfusion identified may not represent the 'peak' perfusion phase, but rather the tail end of the more severe cases. The problem with that theory is that the cohort studied included infants with mild to moderate NE and the authors found a relationship between altered perfusion and outcome even in those children with mild to moderate impairment following NE.

Urine biomarkers of acute kidney injury and association with brain MRI abnormalities in neonatal hypoxic-ischemic encephalopathy

Urine Biomarkers for the Assessment of Acute Kidney Injury in Neonates with Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia

Acute Kidney Injury and Abnormalities on Brain Magnetic Resonance Imaging or Death in Infants with Hypoxic-Ischemic Encephalopathy: A Case-Control Study

Renal oximetry for early acute kidney injury detection in neonates with hypoxic ischemic encephalopathy receiving therapeutic hypothermia

A novel urinary biomarker profile to identify acute kidney injury (AKI) in critically ill neonates: a pilot study

Biomarkers in neonates receiving potential nephrotoxic drugs

Plasmatic profiles of cytokines/chemokines, glial fibrillary acidic protein (GFAP) and MRI brain damage in neonates with hypoxic ischemic encephalopathy (HIE)

Identifying Early Diagnostic Biomarkers Associated with Neonatal Hypoxic-Ischemic Encephalopathy

Prognostic role of acute kidney injury on long-term outcome in infants with hypoxic-ischemic encephalopathy

Predictive Value of MRI in Hypoxic-Ischemic Encephalopathy Treated with Therapeutic Hypothermia

Use of urine neutrophil gelatinase-associated lipocalin for nephrotoxic medication acute kidney injury screening in neonates

Acute kidney injury in neonates with hypoxic ischemic encephalopathy based on serum creatinine decline compared to KDIGO criteria

Urinary Nephrin as a Biomarker of Glomerular Maturation and Injury Is Associated with Acute Kidney Injury and Mortality in Critically Ill Neonates

MicroRNAs as biomarkers of brain injury in neonatal encephalopathy: an observational cohort study

Exploratory Assessment of the Relationship Between Hemoglobin Volume Phase Index, Magnetic Resonance Imaging, and Functional Outcome in Neonates with Hypoxic–Ischemic Encephalopathy

Cerebral blood flow in neonatal encephalopathy: biomarker or potential target?

Biomarkers as predictors of renal damage in neonates undergoing cardiac surgery

Evaluation of Novel Biomarkers for Early Diagnosis of Acute Kidney Injury in Asphyxiated Full-Term Newborns: A Case-Control Study

Serum and urinary biomarkers to predict acute kidney injury in premature infants: a systematic review and meta-analysis of diagnostic accuracy

Evaluation of Urinary S100B Protein Level and Lactate/Creatinine Ratio for Early Diagnosis and Prognostic Prediction of Neonatal Hypoxic-Ischemic Encephalopathy

Advances in Electroencephalographic Biomarkers of Neonatal Hypoxic Ischemic Encephalopathy